POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Clinical trials for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new POORLY DIFFERENTIATED THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Personalized cell therapy takes on resistant cancers
Disease control OngoingThis study tests a treatment made from a patient's own immune cells (called LN-145) for cancers like ovarian, triple-negative breast, anaplastic thyroid, and bone sarcomas that have not responded to standard therapy or have returned. The cells are taken from the tumor, grown in a…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:15 UTC
-
New combo therapy shows promise for rare, aggressive thyroid cancer
Disease control OngoingThis study tests whether combining lenvatinib (a drug that blocks cancer cell growth) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can help people with advanced anaplastic thyroid cancer that cannot be removed by surgery or has spread. The tria…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:12 UTC
-
New combo aims to reboot radioactive iodine in stubborn thyroid cancers
Disease control OngoingThis phase 2 trial tests whether the drug trametinib can help radioactive iodine (RAI) work better in people with advanced thyroid cancer that has returned or spread and no longer responds to RAI alone. About 34 adults with specific genetic types of thyroid cancer will receive tr…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:09 UTC
-
New drug shrinks thyroid tumors before surgery in early trial
Disease control OngoingThis study tests whether giving the drug selpercatinib before surgery can shrink thyroid cancers that have a specific genetic change (RET alteration). About 30 people with advanced or recurrent thyroid cancer will receive the drug and then have surgery. The goal is to see if the …
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:02 UTC
-
New drug cocktail shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with a type of thyroid cancer that no longer responds to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this mix can shrink tumors or slo…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Promising combo therapy targets deadly thyroid cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with aggressive thyroid cancers (anaplastic or poorly differentiated) live longer. About 50 adults with advanced or inoperable cancer will receive different drug combinati…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New drug combo shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tests whether a drug called PDR001, combined with either trametinib or dabrafenib, is safe and effective for people with thyroid cancer that no longer responds to standard radioactive iodine treatment. The trial enrolled 19 adults whose cancer had worsened. The main go…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:01 UTC